Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effects of umbilical cord tissue mesenchymal stem cells (UCX®) on rat sciatic nerve regeneration after neurotmesis injuries

Autor: Gärtner A, Pereira T, Armada-da-Silva PAS, Amado S, Veloso AP, Amorim I, Ribeiro J, Santos JD, Bárcia RN, Cruz P, Cruz H, Luís AL, Santos JM, Geuna S, Maurício AC

Publikováno v: Journal of Stem Cells and Regenerative Medicine, Vol 10, Iss 1, Pp 14-26 (2013)

Peripheral nerves have the intrinsic capacity of self-regeneration after traumatic injury but the extent of the regeneration is often very poor. Increasing evidence demonstrates that mesenchymal stem/stromal cells (MSCs) may play an important role in

Externí odkaz: https://doaj.org/article/5db7dcb0edae42fd9ec89c8269d20425

Corrigendum: Consistent long-term therapeutic efficacy of human umbilical cord matrix-derived mesenchymal stromal cells after myocardial infarction despite individual differences and transient engraftment.

Autor: Laundos TL; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.; Instituto Nacional de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.; Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal., Vasques-Nóvoa F; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.; Instituto Nacional de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.; Cardiovascular RandD Center, Faculty of Medicine of the University of Porto, Porto, Portugal.; Department of Internal Medicine, Centro Hospitalar Universitário São João, Porto, Portugal., Gomes RN; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.; Instituto Nacional de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.; Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal., Sampaio-Pinto V; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.; Instituto Nacional de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.; Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal., Cruz P; ECBio S.A., Amadora, Portugal., Cruz H; ECBio S.A., Amadora, Portugal., Santos JM; ECBio S.A., Amadora, Portugal., Barcia RN; ECBio S.A., Amadora, Portugal., Pinto-do-Ó P; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.; Instituto Nacional de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.; Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal., Nascimento DS; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.; Instituto Nacional de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.; Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2023 Aug 18; Vol. 11, pp. 1265005. Date of Electronic Publication: 2023 Aug 18 (Print Publication: 2023).

Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application.

Autor: O'Rourke B; Sentien Biotechnologies, Inc, Lexington, Massachusetts, USA., Nguyen S; Sentien Biotechnologies, Inc, Lexington, Massachusetts, USA., Tilles AW; Sentien Biotechnologies, Inc, Lexington, Massachusetts, USA., Bynum JA; Blood and Coagulation Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA., Cap AP; Blood and Coagulation Research Program, US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA., Parekkadan B; Sentien Biotechnologies, Inc, Lexington, Massachusetts, USA.; Department of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, Massachusetts, USA.; Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.; Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA., Barcia RN; Sentien Biotechnologies, Inc, Lexington, Massachusetts, USA.

Publikováno v: Stem cells translational medicine [Stem Cells Transl Med] 2021 Jun; Vol. 10 (6), pp. 883-894. Date of Electronic Publication: 2021 Feb 01.

Author Correction: Mesenchymal Stromal Cell Bioreactor for Ex Vivo Reprogramming of Human Immune Cells.

Autor: Allen A; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., Vaninov N; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., Li M; Department of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, Massachusetts, 02114, USA., Nguyen S; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., Singh M; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., Igo P; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., Tilles AW; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., O'Rourke B; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., Miller BLK; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA., Parekkadan B; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA.; Department of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, Massachusetts, 02114, USA.; Harvard Stem Cell Institute, Cambridge, Massachusetts, 02138, USA.; Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, 08854, USA., Barcia RN; Sentien Biotechnologies, Inc., Lexington, MA, 02421, USA. rita.barcia@sentienbiotech.com.

Publikováno v: Scientific reports [Sci Rep] 2020 Sep 17; Vol. 10 (1), pp. 15451. Date of Electronic Publication: 2020 Sep 17.